Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Close on the heels of the first positive findings reported in microbicides and vaccine research ventures, the iPrEx study has shown that a pre-exposure prophylaxis (PrEP) combination drug demonstrates 44% additional protection from HIV infection.

Great results from iPrEx study add to trifecta of good news on prevention